Posts by Sandra Ansanay-Alex
Innobooster Gebert Rüf Stiftung
Apply before 1 May 2026 for the Gebert Rüf Stiftung Innobooster and get up to a CHF 150,000 support Gebert Rüf Stiftungsupports university-based, high-potential businesses from the Venture Kick program with the aim of substantially accelerating their market entry. The funding line is calling for top talents with convincing proposals of how a research &…
Read MoreDigital Health Projectathon
The Digital Health Projectaton, organised by eHealth Suisse is taking place from 22 to 23 September 2026 in Bern The Digital Health Projectathon is an interoperability and conformity test marathon. For several days, participants can test their own products live on site for interoperability and, if necessary, adapt them to the findings during the event. …
Read MoreSyrhatech Completes A CHF 4.5 Million Financing Round
Syrhatech, a French-Swiss CDMO innovating in the development and manufacture of injectable medical devices based in particular on hyaluronic acid, announces the closing of an investment of CHF 4.5 million, completed with strategic investors. Funding for innovation and industrial capacity This investment will enable Syrhatech to strengthen its R&D team at its site in Geneva, and to deploy a…
Read MorePANORAMAI
Panoramai is taking place from 3 to 5 June 2025 at Campus Unlimitrust in Renens Within the Gen AI ecosystem, discover real-life use cases and AI-powered digital transformation stories with entrepreneurs and business experts. The event also aims to enrich the horizons and potential applications of AI by exploring creative perspectives on uses and…
Read MoreInnofood & Co
InnoFood & Co returns for its 5th edition at the Forum Fribourg on 7 May 2026 A must-attend event dedicated to agri-food innovation in Switzerland, Innofood & Co brings together key players in the ecosystem every year: researchers, entrepreneurs, institutions, producers, and project leaders. This day is designed to bring innovative ideas to the fore…
Read MoreNewBiologix Licences Xcell-Eng-HEK293 Cell Line to Recipharm
NewBiologix, a Biopôle-based (Vaud)Swiss biotech innovator, has granted a non-exclusive licence to Recipharm Advanced Bio. The agreement gives Recipharm access to NewBiologix’s Xcell-Eng-HEK293 cell lines, enabling the efficient production of recombinant Adeno-Associated Viruses (rAAVs) for cell and gene therapies. The licensed cell lines offer high-yield, GMP-ready viral production, accelerating the path to clinical trials.…
Read MoreHedera Dx Secures €15 Million Series A
Hedera Dx Raises €15M Series A to Expand Access to Precision Oncology Across Europe Hedera Dx, a Vaud-Based techbio company advancing precision cancer care, announced the successful close of a €15 million Series A financing round. The round was led by Vsquared Ventures, with new investor Tesi joining and strong support from existing backers…
Read MoreTimeline® Named Milestone 1 Award Winner in XPRIZE Healthspan Competition
Timeline®, a leading longevity biotech company (parent company Amazentis in Canton of Vaud) and maker of Mitopure®, has been named a Milestone 1 Award Winner in the prestigious XPRIZE Healthspan competition. Selected from hundreds of global entrants, Timeline is among the Top 40 international teams recognized for advancing innovative, safe, and science-backed solutions to extend…
Read MoreTheia Holding SA Merges With HL Technology SA
Theia Holding SA, a leader in precision technologies for the dental, orthopaedic, and medical fields and HL Technology®, an innovator recognised for patented breakthroughs in medical engineering, are merging. A Strategic Partnership for Innovation and Excellence The merger strengthens Theia Holding SA’s leadership in key sectors — dental, orthopaedic, and broader medical markets…
Read MoreTOP 100 Swiss Startup Award: Vote Now!
The TOP 100 Swiss Startup Award is back! Vote until 20 July 2025 for your favourite Life Sciences start-up. Every year, the TOP 100 Swiss Startup Award showcases the 100 most innovative and promising Swiss startups chosen by a 100-strong jury of leading investors and experts. The TOP 100 Public Vote runs parallel to the expert jury…
Read More